HighQC™ Human iPSC-Derived Natural Killer Cell (PBMC)

Description

HighQC™ Human iPSC-Derived Natural Killer Cell (PBMC) is a human induced pluripotent stem cell-derived NK cell provided by AcceGen. The starting cells are PBMC or CD34⁺ hematopoietic cells from normal donors, which are transfected with Oct3/4, Sox2, Klf4, c-Myc, and other transcription factors, and reprogrammed into iPSCs via a non-integrating vector. These iPSCs are then induced to differentiate into high-purity NK cells (CD56, CD16, CD3⁻), exhibiting typical lymphoid suspension morphology, active natural killer activity, and expression of multiple NK receptors. They are suitable for applications such as tumor immunology, innate immunity research, and immunotherapy drug screening. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast and Bacteria.

Application

• HighQC™ NK cells are generated from human induced pluripotent stem cells (iPSCs), offering a consistent and renewable source of functional innate immune cells. They are ideal for cancer immunotherapy research, cytotoxicity and tumor-killing assays, drug discovery and screening, NK cell engineering, and immune cell biology. These cells support studies in adoptive NK cell therapy, checkpoint blockade mechanisms, and combination immunotherapy strategies, enabling robust preclinical modeling and translational applications.